title: Wilms tumor-1, claudin-1 and ezrin are useful immunohistochemical markers that help to distinguish schwannoma from fibroblastic meningioma.
abstract: The aim of this study is to identify immunohistochemical (IHC) markers that can reliably separate schwannoma (SCHW) and fibroblastic meningioma (FM). We selected 106 cases of intracranial SCHW (n = 56) and FM (n = 50) and constructed a tissue microarray (TMA) of core diameter of 1.0 mm from archival formalin-fixed paraffin-embedded tissue. A TMA-IHC was performed using 14 antibodies. After IHC staining, 98 cores were found suitable for evaluation. The IHC staining was scored as 0-2+ (0, negative; 1+, weak and/or focal 2+ strong and/or diffuse positive). A discriminant analysis (DA) (Wilks'Lambda test) was performed to assess the relative importance of these biomarkers in classifying the two groups FM and SCHW. It showed that WT-1 (Wilks'λ 0.085, p < 0.001), EMA (Wilks'λ 0.253, p < 0.001), S100 (Wilks'λ 0.487, p < 0.001), Claudin-1 (Wilks' λ 0.57, p < 0.001) and Ezrin (Wilks'λ 0.656, p < 0.001), SPARC (Wilks'λ 0.751, p < 0.01), NP-Y (Wilks'λ, 0.819, p < 0.001) and EGFR (Wilks'λ 0.845, p = 0.026) were some of the statistically significant markers that discriminated SCHW and FM. For sensitivity and specificity for SCHW the significant markers [Area under the curve (95% CI), p-value] by ROC analysis were WT-1 [0.990(0.000, 1.000), <0.001], S100 [0.880(0.808, 0.951), <0.001] while for diagnosing FM the most sensitive and specific markers were EMA [0.957(0.914, 1.000), <. 001], Claudin-1 [0.857(0.782, 0.932), <0.001] and ezrin [0.792(0.700,0.884),<0.001]. WT-1, Claudin-1 and Ezrin may be potentially useful immunohistochemical adjuncts to EMA and S100 that differentiate SCHW from FM.
authors: Safdarjung Hospital Campus, National Institute of Pathology (ICMR), Room 602, 6th floor, New Delhi, 110029, India. dravninder@yahoo.co.in
authors: Avninder
authors: A
authors: Singh
authors: Ashwani Kumar
authors: AK
authors: Mishra
authors: Kris
authors: K
authors: Ylaya
authors: Stephen M
authors: SM
authors: Hewitt
authors: Karam Chand
authors: KC
authors: Sharma
authors: Sunita
authors: S
authors: Saxena
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D062445:Claudin-1; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D008579:Meningioma / Q000175:diagnosis / Q000378:metabolism*; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism; D009367:Neoplasm Staging; D009442:Neurilemmoma / Q000175:diagnosis / Q000378:metabolism*; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D009418:S100 Proteins / Q000378:metabolism; D046888:Tissue Array Analysis; D025721:WT1 Proteins / Q000378:metabolism*; D055815:Young Adult; D000099149:Ezrin
chemical_list: D014408:Biomarkers, Tumor; D062445:Claudin-1; D003598:Cytoskeletal Proteins; D008565:Membrane Proteins; D018396:Mucin-1; D009418:S100 Proteins; D025721:WT1 Proteins; D000099149:Ezrin; C568108:CLDN1 protein, human